TRIPLE NEGATIVE BREAST NEOPLASMS

This early-phase study tested a new drug (TAK-676) combined with pembrolizumab after radiation therapy in 34 adults with lung, triple-negative breast, or head/neck cancers that had stopped responding to standard treatments. The main goals were to check safety, side effects, and f…

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with a fast-returning, advanced form of triple-negative breast cancer live longer. About 595 participants whose cancer had spread or couldn't be surgically removed were rand…

This early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with pembrolizumab, in 182 adults with advanced solid tumors (including lung and triple-negative breast cancers). The main goal was to check safety and how the drug moves through the b…

This study looked at 462 people with advanced triple-negative breast cancer that had not spread before. After initial chemotherapy, some received a combination of olaparib and pembrolizumab, while others got more chemo plus pembrolizumab. The goal was to see if the new combo help…

This phase 3 trial tested whether adding the immunotherapy drug avelumab after standard treatment (surgery and chemotherapy) helps prevent cancer from coming back in people with high-risk triple negative breast cancer. The study enrolled 474 adults who had already completed curat…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with triple-negative breast cancer (TNBC). Over 1,100 participants received either pembrolizumab plus chemo or a placebo plus chemo before surgery, then continued pembroliz…

This study tested a combination of two drugs, ladiratuzumab vedotin (LV) and pembrolizumab, in 185 people with advanced triple-negative breast cancer that had spread. The main goals were to check for side effects and see if the drugs could shrink tumors. The trial found that the …